In Brief: Genzyme correction
This article was originally published in The Gray Sheet
Executive SummaryGenzyme correction: Genzyme Corp. has withdrawn its premarket approval application for its Sepracoat anti-adhesion product following a negative panel recommendation in May. "The Gray Sheet" incorrectly reported Sept. 1 (p. 3) that the PMA was sponsored by Genzyme Tissue Repair and was still pending at the agency...
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.